Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Comparison of the cardiac electrophysiology and general toxicology of two formulations of intravenous amiodarone in dogs.

Cushing DJ, Cooper WD, Gralinski MR, Lipicky RJ, Kudenchuk PJ, Kowey PR.

Cardiovasc Toxicol. 2009 Sep;9(3):126-33. doi: 10.1007/s12012-009-9044-4.

PMID:
19554478
2.

Evaluation of the effects of PM101, a cyclodextrin-based formulation of intravenous amiodarone, on blood pressure in healthy humans.

Cushing DJ, Adams MP, Cooper WD, Zhang B, Lipicky RJ, Kowey PR.

Am J Cardiol. 2009 Oct 15;104(8):1152-7. doi: 10.1016/j.amjcard.2009.06.010.

PMID:
19801040
3.

PM101: a cyclodextrin-based intravenous formulation of amiodarone devoid of adverse hemodynamic effects.

Cushing DJ, Kowey PR, Cooper WD, Massey BW, Gralinski MR, Lipicky RJ.

Eur J Pharmacol. 2009 Apr 1;607(1-3):167-72. doi: 10.1016/j.ejphar.2009.02.009.

PMID:
19232340
4.

The hypotensive effect of intravenous amiodarone is sustained throughout the maintenance infusion period.

Cushing DJ, Cooper WD, Gralinski MR, Lipicky RJ.

Clin Exp Pharmacol Physiol. 2010 Mar;37(3):358-61. doi: 10.1111/j.1440-1681.2009.05303.x.

PMID:
19793107
5.

PM101: intravenous amiodarone formulation changes can improve medication safety.

Souney PF, Cooper WD, Cushing DJ.

Expert Opin Drug Saf. 2010 Mar;9(2):319-33. doi: 10.1517/14740331003586811. Review.

PMID:
20074019
6.
7.

Pharmacology and toxicology of a new aqueous formulation of intravenous amiodarone (Amio-Aqueous) compared with Cordarone IV.

Somberg JC, Cao W, Cvetanovic I, Ranade V, Molnar J.

Am J Ther. 2005 Jan-Feb;12(1):9-16.

PMID:
15662287
8.

Bioequivalence of 2 intravenous amiodarone formulations in healthy participants.

Cushing DJ, Adams MP, Cooper WD, Kowey PR, Lipicky RJ.

J Clin Pharmacol. 2009 Apr;49(4):407-15. doi: 10.1177/0091270008330156.

PMID:
19246726
9.
10.
11.

Prospective, randomized comparison of conventional and high dose loading regimens of amiodarone in the treatment of ventricular tachycardia.

Kalbfleisch SJ, Williamson B, Man KC, Vorperian V, Hummel JD, Hasse C, Strickberger SA, Calkins H, Langberg JJ, Morady F.

J Am Coll Cardiol. 1993 Nov 15;22(6):1723-9.

12.

Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. The Intravenous Amiodarone Multicenter Investigators Group.

Scheinman MM, Levine JH, Cannom DS, Friehling T, Kopelman HA, Chilson DA, Platia EV, Wilber DJ, Kowey PR.

Circulation. 1995 Dec 1;92(11):3264-72.

13.

NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).

National Toxicology Program ..

Natl Toxicol Program Tech Rep Ser. 1993 Sep;422:1-340.

15.

Effects of acute intravenous and chronic oral amiodarone on defibrillation energy requirements.

Fain ES, Lee JT, Winkle RA.

Am Heart J. 1987 Jul;114(1 Pt 1):8-17.

PMID:
3604876
17.

Lack of a hypotensive effect with rapid administration of a new aqueous formulation of intravenous amiodarone.

Somberg JC, Timar S, Bailin SJ, Lakatos F, Haffajee CI, Tarjan J, Paladino WP, Sarosi I, Kerin NZ, Borbola J, Bridges DE, Molnar J; Amio-Aqueous Investigators..

Am J Cardiol. 2004 Mar 1;93(5):576-81.

PMID:
14996582
19.

Hemodynamic and surface electrocardiographic effects of a new aqueous formulation of intravenous amiodarone.

Gallik DM, Singer I, Meissner MD, Molnar J, Somberg JC.

Am J Cardiol. 2002 Nov 1;90(9):964-8.

PMID:
12398963
20.

Hypotensive action of commercial intravenous amiodarone and polysorbate 80 in dogs.

Gough WB, Zeiler RH, Barreca P, El-Sherif N.

J Cardiovasc Pharmacol. 1982 May-Jun;4(3):375-80.

PMID:
6177932
Items per page

Supplemental Content

Support Center